Global Valsartan Drug Market Size, Share and Trends Analysis Report, By Type (40 mg, 80 mg, 160 mg, and 320 mg), By Disease Heart Failure and Hypertension) Forecast (2022-2028)

The global valsartan drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Valsartan drug is used in the treatment of body ailments such as heart failure and high blood pressure. This drug increases the survival rate of patients after they have suffered a heart attack. After having a cardiac arrest, patients need to go to the hospital for regular checkups and follow-ups. Consistent use of this drug reduces the chance of patients having further heart conditions which would lead to mortality. Valsartan drug belongs to a category of drugs which are known as angiotensin receptor blockers. This drug mainly works on blood vessels in the body through which blood flow takes place. It relaxes the blood vessels and ensures a free flow of blood through them. It is necessary to reduce high blood pressure in the human body as it leads to serious health conditions such as strokes, heart attacks, and kidney issues. This, in turn, is resulting an increasing demand for valsartan drugs. Increasing cases of heart failure across the globe are further expected to drive the market during the forecast period.

Some major players in the market are Novartis International AG, Mylan NV, and Teva Pharmaceutical Industries Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in Dec 2021, Dr.Reddy’s Laboratories, Ltd. launched a valsartan tablet in the US market. This drug is used in the treatment of high blood pressure and heart failure. The valsartan tablet is approved by Food and Drug Administration in the US and is a major equivalent of a Diovan drug. Valsartan tablets are available in 80mg, 160mg, and 320mg doses.

Further, in Feb 2021, the US Food and Drug Administration (FDA) has approved a therapy that would be effective in patients with heart failure and preserved ejection fraction. This therapy is named sacubitril/valsartan and is prepared by Novartis AG. This drug is found useful in reducing the chances of patients going to the hospital who have chronic heart disease and preserved ejection fraction. Patients who have left ventricular ejection fraction below normal have found this treatment to be effective. FDA’s decision in this regard was positive as previously, the trial of paragon HF was done by health experts, however, it was lacking in its primary endpoint and thus sacubitril/valsartan was approved. Novartis AG declared that in the US more than 6 million people have chronic heart failure and that about 5 million people may be its target market for this drug.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Disease
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Novartis International AG, Mylan NV, and Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Valsartan Drug Market Report By Segment

By Type

• 40 mg
• 80 mg
• 160 mg
• 320 mg

By Disease

• Heart Failure
• Hypertension

Global Valsartan Drugarket Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa